Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
时间:2024-06-26 18:23:56 阅读(143)
Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent.
The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
上一篇:Sebi working on ASBA-like facility for secondary market transactions as well
下一篇:World Bank retains India growth forecasts for FY24 and FY25
猜你喜欢
- Charminar Express coaches derail at Telangana’s Nampally station, 5 injured
- Bizarre markets, scarred bond yields- Markets await RBI action, Ukraine peace talks for respite- Lakshmi Iyer
- Chinese EV makers set sight on Hong Kong to drive global expansion plans
- Sebi to auction two properties of Swar Agrotech on August 7
- Closing Bell- Indian Indices extended gains for yet another session- Nifty Settles Above 19,230, Sensex Over 64,360
- Bharti Airtel, Delhivery, NTPC, Dabur, GAIL India, VIP Clothing, City Union Bank stocks in focus on 21 Dec
- Bulls on the charge after Fed signals smaller hikes
- Buy these two stocks for near term gains while Nifty continues to face resistance at 15,900
- CDSL Stock Rating- Brokerage upgrades to ‘Buy’, expects solid growth recovery; check target price